3 Pathology Labs Chain, Agrochemicals Company and Personal Care Brands Company Stocks With a Strong Future Roadmap: Dr. Lal PathLabs, PI Industries and Honasa Consumer
- November 18, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Dr. Lal PathLabs, PI Industries and Honasa Consumer: ROE of 11.8% to 20.1% and FY22 to FY26 revenue CAGR of 6.8% to 26.6%. Prices as of 17 Nov 2026.
Quick Answer
The three pathology lab, agrochemical and baby care stocks to watch are Dr. Lal PathLabs, PI Industries and Honasa Consumer. Their return on equity ranges from 11.8% to 20.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 26.6%. Dr. Lal PathLabs has the highest return on equity at 20.1%, while Honasa Consumer has the fastest revenue growth at 26.6% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.
Pathology lab, agrochemical and baby care stocks give investors a way to track businesses that sit close to everyday demand in India. Dr. Lal PathLabs, PI Industries and Honasa Consumer cover a pathology labs chain, an agrochemicals company and a personal care brands company.
This list covers three pathology lab, agrochemical and baby care stocks with complete current figures: Dr. Lal PathLabs, PI Industries and Honasa Consumer. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pathology Lab, Agrochemical and Baby Care Stocks?
Pathology lab, agrochemical and baby care stocks are listed companies that run pathology labs and collection centres across India, make crop protection chemicals and offer custom manufacturing for global firms, and sell baby care, skin care and hair care brands online and in stores. Their earnings depend on test volumes, crop chemical demand and brand sales.
Pathology Lab, Agrochemical and Baby Care Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Dr. Lal PathLabs | 1,980.2 | 30,949 | 56.6 | 59.6 | 20.1 | 0.08 |
| PI Industries | 1,672 | 33,166 | 28.5 | 23.3 | 11.8 | 0.03 |
| Honasa Consumer | 517.8 | 14,399 | 57.7 | 52.5 | 14.2 | 0.10 |
On valuation, Dr. Lal PathLabs trades at a P/E below the industry P/E, while PI Industries and Honasa Consumer trade above it, which reflects the growth the market already expects. Readers comparing pathology lab, agrochemical and baby care stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pathology lab, agrochemical and baby care stocks can use the coming numbers to test whether growth is holding.
Why Do Pathology Lab, Agrochemical and Baby Care Stocks Have a Strong Roadmap in India?
Pathology lab, agrochemical and baby care stocks have a strong roadmap in India because wider use of preventive health tests, steady farm input demand and rising online buying of personal care brands keep widening the market for these companies.
- Pathology. Doctors order more routine tests.
- Agrochemicals. Farmers and global firms need crop chemicals.
- Personal care. Shoppers try new digital brands.
Why Dr. Lal PathLabs Features Among These Pathology Lab, Agrochemical and Baby Care Stocks
Among the pathology lab, agrochemical and baby care stocks on this list, Dr. Lal PathLabs is one of India’s best-known diagnostics companies, operating a national reference laboratory with a hub-and-spoke network of labs, patient service centres and collection points.
The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6.
Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore.
Roadmap: Its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.
What to watch: Follow test volumes per patient and the balance between routine and specialised tests.
Why PI Industries Features Among These Pathology Lab, Agrochemical and Baby Care Stocks
Among the diagnostics chain, crop science and personal care shares on this list, PI Industries is a Udaipur-based agrochemical and custom synthesis company. It sells crop protection products in India and manufactures complex molecules for global innovators, and it has added pharma and specialty chemistry capabilities.
Revenue rose from Rs 5,401 crore in FY22 to Rs 7,024 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 844 crore in FY22 to Rs 1,321 crore in FY26, which works out to a compound annual growth rate of 11.9%.
The company has a return on equity of 11.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 33,166 crore. The stock trades at a P/E of 28.5, above the industry P/E of 23.3.
Roadmap: The company is building long-term supply contracts for global customers, launching new crop protection brands and widening into pharma and other specialty areas. Strong research and plant capacity support its pipeline.
What to watch: Check the growth of custom synthesis orders and new product launches.
Why Honasa Consumer Features Among These Pathology Lab, Agrochemical and Baby Care Stocks
Among the three companies on this list, Honasa Consumer, based in Gurugram, owns beauty and personal care brands including Mamaearth, The Derma Co, Aqualogica and Dr. Sheth’s.
In the June 2026 quarter, revenue grew 25.7% year on year to Rs 778 crore, while net profit rose 118.8% to Rs 90.5 crore. Revenue rose from Rs 964 crore in FY22 to Rs 2,476 crore in FY26, a compound annual growth rate of 26.6%.
Net profit grew from Rs 111 crore in FY24 to Rs 200 crore in FY26, which works out to a compound annual growth rate of 34.6%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 14,399 crore. The stock trades at a P/E of 57.7, above the industry P/E of 52.5.
Roadmap: The company is growing its brand portfolio, widening offline retail and building a presence in premium segments. A digital-first approach and a growing base of repeat customers support its roadmap.
What to watch: Track brand-level growth and spending on advertising.
Dr. Lal PathLabs vs PI Industries vs Honasa Consumer on Key Financials
The table below sets the three pathology lab, agrochemical and baby care stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Dr. Lal PathLabs | 2,140 | 2,864 | 7.6% | 510 | 17.8% |
| PI Industries | 5,401 | 7,024 | 6.8% | 1,321 | 18.8% |
| Honasa Consumer | 964 | 2,476 | 26.6% | 200 | 8.1% |
Dr. Lal PathLabs posts the highest return on equity in this group at 20.1%. PI Industries has the largest FY26 revenue at Rs 7,024 crore, and Honasa Consumer shows the fastest revenue growth with a 26.6% compound annual rate. A useful habit with pathology lab, agrochemical and baby care stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Pathology Lab, Agrochemical and Baby Care Stocks
Every theme carries risks that deserve a check before any decision. For these pathology lab, agrochemical and baby care stocks, the main points are: Long-term diagnostics chain, crop science and personal care shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Test volumes. Footfall and test mix can vary with seasons.
- Season and monsoon. Crop protection sales follow rain and pest cycles.
- Consumer spending. Sales follow festivals, incomes and consumer mood.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pathology lab, agrochemical and baby care stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pathology Lab, Agrochemical and Baby Care Stocks
Pathology lab, agrochemical and baby care stocks work best when investors track growth, valuation and return on equity side by side. Dr. Lal PathLabs, PI Industries and Honasa Consumer each have a clear plan to grow. Based on the 17 November 2026 close, Dr. Lal PathLabs trades at Rs 1,980.2, PI Industries at Rs 1,672 and Honasa Consumer at Rs 517.8. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pathology lab, agrochemical and baby care stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pathology lab, agrochemical and baby care stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pathology lab, agrochemical and baby care stocks?
Ans. Pathology lab, agrochemical and baby care stocks are listed companies that run pathology labs and collection centres across India, make crop protection chemicals and offer custom manufacturing for global firms, and sell baby care, skin care and hair care brands online and in stores. Their earnings depend on test volumes, crop chemical demand and brand sales. This list looks at three of them, Dr. Lal PathLabs, PI Industries and Honasa Consumer, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.
Which pathology lab, agrochemical and baby care stocks are covered in this list?
Ans. This list covers Dr. Lal PathLabs, PI Industries and Honasa Consumer. Based on the 17 November 2026 close, Dr. Lal PathLabs traded at Rs 1,980.2, PI Industries at Rs 1,672 and Honasa Consumer at Rs 517.8. Their return on equity ranges from 11.8% to 20.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 26.6%.
Why do pathology lab, agrochemical and baby care stocks have a strong future roadmap in India?
Ans. Pathology lab, agrochemical and baby care stocks have a strong roadmap in India because wider use of preventive health tests, steady farm input demand and rising online buying of personal care brands keep widening the market for these companies. The main drivers are as follows. Pathology. Doctors order more routine tests. Agrochemicals. Farmers and global firms need crop chemicals. Personal care. Shoppers try new digital brands. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Dr. Lal PathLabs performed financially?
Ans. Revenue rose from Rs 2,140 crore in FY22 to Rs 2,864 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 350 crore in FY22 to Rs 510 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 18.9% year on year to Rs 830 crore, while net profit rose 27.2% to Rs 170 crore. The company has a return on equity of 20.1%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 30,949 crore. The stock trades at a P/E of 56.6, below the industry P/E of 59.6. Looking ahead, its asset-light collection network lets the company enter new towns without heavy capital spending. Growth levers include test menu expansion in oncology and genetics, wellness packages and deeper reach in North and East India through franchise and direct collection centres.
How has PI Industries performed financially?
Ans. Revenue rose from Rs 5,401 crore in FY22 to Rs 7,024 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 844 crore in FY22 to Rs 1,321 crore in FY26, which works out to a compound annual growth rate of 11.9%. The company has a return on equity of 11.8%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 33,166 crore. The stock trades at a P/E of 28.5, above the industry P/E of 23.3. Looking ahead, the company is building long-term supply contracts for global customers, launching new crop protection brands and widening into pharma and other specialty areas. Strong research and plant capacity support its pipeline.
How has Honasa Consumer performed financially?
Ans. Revenue rose from Rs 964 crore in FY22 to Rs 2,476 crore in FY26, a compound annual growth rate of 26.6%. Net profit grew from Rs 111 crore in FY24 to Rs 200 crore in FY26, which works out to a compound annual growth rate of 34.6%. In the June 2026 quarter, revenue grew 25.7% year on year to Rs 778 crore, while net profit rose 118.8% to Rs 90.5 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 14,399 crore. The stock trades at a P/E of 57.7, above the industry P/E of 52.5. Looking ahead, the company is growing its brand portfolio, widening offline retail and building a presence in premium segments. A digital-first approach and a growing base of repeat customers support its roadmap.
What risks should investors check before buying pathology lab, agrochemical and baby care stocks?
Ans. Investors should check a few risks before buying pathology lab, agrochemical and baby care stocks. Test volumes. Footfall and test mix can vary with seasons. Season and monsoon. Crop protection sales follow rain and pest cycles. Consumer spending. Sales follow festivals, incomes and consumer mood. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pathology lab, agrochemical and baby care stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.